RA Capital Management’s OnKure Therapeutics OKUR Stock Holding History

RA Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.2M	Hold	3,998,333	–	–	0.16%	66
2026 Q1	$16.6M	Buy	+3,998,333	New	+$12.3M	0.18%	66
2021 Q4	–	Sell	-6,222	Closed	-$464K	–	103
2021 Q3	$464K	Hold	6,222	–	–	0.01%	94
2021 Q2	$580K	Buy	+6,222	New	+$694K	0.01%	92

Other funds holding OKUR

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RA Capital Management's OKUR Position: Q2 2026 in Review

RA Capital Management held its OnKure Therapeutics (OKUR) position steady in Q2 2026 at 3,998,333 shares worth $18.2M. The position accounts for 0.16% of the portfolio, ranked #66.

RA Capital Management first reported a position in OKUR in Q2 2021 and has held it in 4 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

RA Capital Management held 3,998,333 shares of OnKure Therapeutics worth $18.2M as of Q2 2026.
RA Capital Management left its OnKure Therapeutics share count unchanged in Q2 2026.
OnKure Therapeutics made up 0.16% of RA Capital Management's portfolio in Q2 2026, its #66 holding.
RA Capital Management first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 4 quarters since.
75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.